COMMUNIQUÉS West-GlobeNewswire

-
Aclaris Therapeutics Announces Leadership Transition
28/07/2025 -
Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives
28/07/2025 -
New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox
28/07/2025 -
DLH to Announce Fiscal 2025 Third Quarter Financial Results
28/07/2025 -
AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
28/07/2025 -
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments in the Deramiocel Program for the Treatment of Duchenne Muscular Dystrophy
28/07/2025 -
Eleos Deepens Post-Acute Care Mission with Home Health, Palliative, and Hospice Care Expansion
28/07/2025 -
Carlsmed’s aprevo® Powers First Personalized Cervical Spine Surgery
28/07/2025 -
Full Alliance Group Reports Second Quarter Preliminary results, Unveils Expansion into High-Growth Men's Wellness Personal Care and Health Virility segment, Association Digital Benefits, and Expands its Contract Manufacturing Markets
28/07/2025 -
Unity Consortium Announces Publication of Journal of Adolescent Health Supplement: “Expert Perspectives on Adolescent Immunization Platform Visits”
28/07/2025 -
Global Alzheimer’s Platform Foundation and Genentech Collaborate to Expand Access to Alzheimer’s Research
28/07/2025 -
BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants.
28/07/2025 -
BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants.
28/07/2025 -
Serina Therapeutics to Present at the BTIG Virtual Biotechnology Conference
28/07/2025 -
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate
28/07/2025 -
Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
28/07/2025 -
FDA Approves SKYTROFA® (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency
28/07/2025 -
Boehringer Ingelheim and Re-Vana Therapeutics Announce Strategic Collaboration to Develop Long-Acting Ophthalmic Therapies
28/07/2025 -
Cannara Biotech enregistre son chiffre d’affaires et sa rentabilité les plus élevés depuis sa création au troisième trimestre de l’exercice 2025
28/07/2025
Pages